title: The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.
abstract: OBJECTIVE
  Serum sodium has been suggested to incorporate into the model for end-stage liver disease to enhance its prognostic ability for cirrhosis. A mathematical equation based on model for end-stage liver disease and sodium, known as "MELD-Na", was developed for outcome prediction for cirrhosis. The severity of liver cirrhosis is a key component to predict survival in patients with hepatocellular carcinoma. This study investigated the prognostic role of MELD-Na for hepatocellular carcinoma.
  
  
  METHODS
  A total of 535 unselected hepatocellular carcinoma patients were prospectively enrolled to evaluate the performance of MELD-Na.
  
  
  RESULTS
  The MELD-Na was better than model for end-stage liver disease in predicting 6-month mortality by comparing the area under receiver operating characteristic curve (0.782 vs. 0.761, p=0.101). MELD-Na, but not model for end-stage liver disease, was an independent predictor associated with 6-month mortality in multivariate logistic regression analysis (odds ratio: 1.14, p=0.001). In the survival analysis, MELD-Na also independently predicted mortality, with an additional risk of 4.3% per unit increment of the score (p<0.001). Patients with MELD-Na scores between 10 and 20 and scores >20 had 2.1-fold (p<0.001) and 7.5-fold (p<0.001) risk of mortality, respectively, compared to patients with a score <10 in the Cox proportional hazard model.
  
  
  CONCLUSIONS
  The MELD-Na score is a feasible and independent prognostic predictor for both short- and long-term outcome predictions in patients with hepatocellular carcinoma.
authors.affiliation: Department of Medicine, Taipei Veterans General Hospital, National Yang-Ming University School of Medicine, Taipei, Taiwan. tihuo@vghtpe.gov.tw
authors.forename: T-I
authors.initials: TI
authors.lastname: Huo
authors.forename: H-C
authors.initials: HC
authors.lastname: Lin
authors.forename: C-Y
authors.initials: CY
authors.lastname: Hsia
authors.forename: Y-H
authors.initials: YH
authors.lastname: Huang
authors.forename: J-C
authors.initials: JC
authors.lastname: Wu
authors.forename: J-H
authors.initials: JH
authors.lastname: Chiang
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Chiou
authors.forename: W-Y
authors.initials: WY
authors.lastname: Lui
authors.forename: P-C
authors.initials: PC
authors.lastname: Lee
authors.forename: S-D
authors.initials: SD
authors.lastname: Lee
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000401:mortality*; D002423:Cause of Death; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000401:mortality*; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012964:Sodium / Q000097:blood*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D012964:Sodium